Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Scilex Holding Company (SCLX : NSDQ)

• Company Description    Scilex Holding Company is a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain. Scilex Holding Company, formerly known as Vickers Vantage Corp. I, is based in PALO ALTO, Calif. Number of Employees: 115

• Price / Volume Information    Yesterday's Closing Price: $26.28 Daily Weekly Monthly 20 Day Moving Average: 213,275 shares Shares Outstanding: 6.96 (millions) Market Capitalization: $182.80 (millions) Beta: 1.34 52 Week High: $32.92 52 Week Low: $3.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 51.30% 48.64% 12 Week 448.64% 398.36% Year To Date 76.27% 51.87%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 960 SAN ANTONIO ROAD - PALO ALTO,CA 94303 USA ph: 650-516-4310 fax: - investorrelations@scilexholding.com http://www.scilexholding.com

• General Corporate Information    Officers Jaisim Shah - Chief Executive Officer; President and Director Henry Ji - Executive Chairperson and Director Stephen Ma - Chief Financial Officer Dorman Followwill - Director Jay Chun - Director Peer Information Scilex Holding Company (CORR.) Scilex Holding Company (RSPI) Scilex Holding Company (CGXP) Scilex Holding Company (BGEN) Scilex Holding Company (GTBP) Scilex Holding Company (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 80880W205 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 01/16/26 Share - Related Items Shares Outstanding: 6.96 Most Recent Split Date: 4.00 (0.03:1) Beta: 1.34 Market Capitalization: $182.80 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 01/16/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 4.13 EPS Growth vs. Year Ago Period: -17.90% vs. Previous Quarter: -228.32% Sales Growth vs. Year Ago Period: -39.55% vs. Previous Quarter: 97.76% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - -109.95 03/31/25 - -82.65 12/31/24 - -80.31 Current Ratio 06/30/25 - 0.11 03/31/25 - 0.10 12/31/24 - 0.16 Quick Ratio 06/30/25 - 0.10 03/31/25 - 0.09 12/31/24 - 0.15 Operating Margin 06/30/25 - -221.28 03/31/25 - -153.57 12/31/24 - -138.07 Net Margin 06/30/25 - -179.12 03/31/25 - -146.93 12/31/24 - -128.66 Pre-Tax Margin 06/30/25 - -183.01 03/31/25 - -146.94 12/31/24 - -128.66 Book Value 06/30/25 - -35.82 03/31/25 - -30.42 12/31/24 - -27.68 Inventory Turnover 06/30/25 - 5.06 03/31/25 - 5.21 12/31/24 - 5.86 Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©